;PMID: 8753804 ;source_file_1015.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..54] = [t:0..54] ;1)sentence:[e:60..229] = [t:60..229] ;2)section:[e:233..288] = [t:233..288] ;3)section:[e:292..423] = [t:292..423] ;4)sentence:[e:427..619] = [t:427..619] ;5)sentence:[e:620..792] = [t:620..792] ;6)sentence:[e:793..895] = [t:793..895] ;7)sentence:[e:896..1091] = [t:896..1091] ;8)sentence:[e:1092..1200] = [t:1092..1200] ;9)sentence:[e:1201..1306] = [t:1201..1306] ;10)sentence:[e:1308..1388] = [t:1308..1388] ;11)sentence:[e:1390..1486] = [t:1390..1486] ;12)sentence:[e:1487..1531] = [t:1487..1531] ;13)sentence:[e:1532..1679] = [t:1532..1679] ;14)sentence:[e:1680..1785] = [t:1680..1785] ;15)sentence:[e:1786..1905] = [t:1786..1905] ;16)section:[e:1909..1953] = [t:1909..1953] ;Token/POS Errors ;ERROR_Token in entity file but not tree[1313..1317] like ;section 0 Span:0..54 ;Biochem Biophys Res Commun. 1996 Aug 14;225(2):585-92. (SEC (FRAG (NNP:[0..7] Biochem) (NNP:[8..15] Biophys) (NNP:[16..19] Res) (NNP:[20..26] Commun) (RB:[26..27] .) (CD:[28..32] 1996) (IN:[33..36] Aug) (CD:[37..44] 14;225-LRB-) (CD:[44..45] 2) (-RRB-:[45..46] -RRB-) (CD:[46..50] :585) (::[50..51] -) (CD:[51..53] 92) (.:[53..54] .))) ;sentence 1 Span:60..229 ;The opposing effects of retinoic acid and phorbol esters converge to a common ; response element in the promoter of the rat cholesterol 7 alpha-hydroxylase ;gene (CYP7A). ;[84..97]:substance:"retinoic acid" ;[102..116]:substance:"phorbol esters" ;[163..171]:substance:"promoter" ;[222..227]:cyp450:"CYP7A" (SENT (S-HLN (NP-SBJ (NP (DT:[60..63] The) (JJ:[64..72] opposing) (NNS:[73..80] effects)) (PP (IN:[81..83] of) (NP (NP (JJ:[84..92] retinoic) (NN:[93..97] acid)) (CC:[98..101] and) (NP (NN:[102..109] phorbol) (NNS:[110..116] esters))))) (VP (VBP:[117..125] converge) (PP-CLR (TO:[126..128] to) (NP (DT:[129..130] a) (JJ:[131..137] common) (NN:[139..147] response) (NN:[148..155] element))) (PP (IN:[156..158] in) (NP (NP (DT:[159..162] the) (NN:[163..171] promoter)) (PP (IN:[172..174] of) (NP (NP (DT:[175..178] the) (NN:[179..182] rat) (NN:[183..194] cholesterol) (NML (CD:[195..196] 7) (NN:[197..214] alpha-hydroxylase)) (NN:[215..219] gene)) (NP (-LRB-:[221..222] -LRB-) (NN:[222..227] CYP7A) (-RRB-:[227..228] -RRB-))))))) (.:[228..229] .))) ;section 2 Span:233..288 ;Crestani M, Sadeghpour A, Stroup D, Galli G, Chiang JY. (SEC (FRAG (NNP:[233..241] Crestani) (NNP:[242..244] M,) (NNP:[245..255] Sadeghpour) (NNP:[256..257] A) (,:[257..258] ,) (NNP:[259..265] Stroup) (NNP:[266..267] D) (,:[267..268] ,) (NNP:[269..274] Galli) (NNP:[275..276] G) (,:[276..277] ,) (NNP:[278..284] Chiang) (NNP:[285..287] JY) (.:[287..288] .))) ;section 3 Span:292..423 ;Department of Biochemistry and Molecular Pathology, Northeastern Ohio ;Universities College of Medicine, Rootstown 44272-0095, USA. (SEC (FRAG (NNP:[292..302] Department) (IN:[303..305] of) (NNP:[306..318] Biochemistry) (CC:[319..322] and) (NNP:[323..332] Molecular) (NNP:[333..342] Pathology) (,:[342..343] ,) (DT:[344..356] Northeastern) (NNP:[357..361] Ohio) (NNP:[363..375] Universities) (NNP:[376..383] College) (IN:[384..386] of) (NNP:[387..395] Medicine) (,:[395..396] ,) (NNP:[397..406] Rootstown) (CD:[407..412] 44272) (CD:[412..417] -0095) (,:[417..418] ,) (NNP:[419..422] USA) (.:[422..423] .))) ;sentence 4 Span:427..619 ;The activity of the rat CYP7A/luciferase reporter gene was increased ;five-fold by all-trans retinoic acid (atRA) or 9-cis retinoic acid (9cRA) in ;transient transfection assay in HepG2 cells. ;[496..505]:quantitative-value:"five-fold" ;[510..533]:substance:"all-trans retinoic acid" ;[535..539]:substance:"atRA" ;[544..563]:substance:"9-cis retinoic acid" ;[565..569]:substance:"9cRA" (SENT (S (NP-SBJ-1 (NP (DT:[427..430] The) (NN:[431..439] activity)) (PP (IN:[440..442] of) (NP (DT:[443..446] the) (NN:[447..450] rat) (NML (NN:[451..456] CYP7A) (SYM:[456..457] /) (NN:[457..467] luciferase)) (NN:[468..476] reporter) (NN:[477..481] gene)))) (VP (VBD:[482..485] was) (VP (VBN:[486..495] increased) (NP-1 (-NONE-:[495..495] *)) (ADVP-EXT (QP (CD:[496..500] five) (HYPH:[500..501] -) (RB:[501..505] fold))) (PP (IN:[507..509] by) (NP-LGS (NP (NP (NN:[510..519] all-trans) (JJ:[520..528] retinoic) (NN:[529..533] acid)) (NP (-LRB-:[534..535] -LRB-) (NN:[535..539] atRA) (-RRB-:[539..540] -RRB-))) (CC:[541..543] or) (NP (NP (NN:[544..549] 9-cis) (JJ:[550..558] retinoic) (NN:[559..563] acid)) (NP (-LRB-:[564..565] -LRB-) (NN:[565..569] 9cRA) (-RRB-:[569..570] -RRB-))))) (PP (IN:[571..573] in) (NP (JJ:[574..583] transient) (NN:[585..597] transfection) (NN:[598..603] assay))) (PP-LOC (IN:[604..606] in) (NP (NN:[607..612] HepG2) (NNS:[613..618] cells))))) (.:[618..619] .))) ;sentence 5 Span:620..792 ;Cotransfection with retinoid X receptor (RXR) stimulated the promoter ;activity in the absence of ligand, however, addition of atRA inhibited the ;transcriptional activity. ;[640..659]:substance:"retinoid X receptor" ;[661..664]:substance:"RXR" ;[682..690]:substance:"promoter" ;[718..724]:substance:"ligand" ;[748..752]:substance:"atRA" (SENT (S (NP-SBJ (NP (NN:[620..634] Cotransfection)) (PP (IN:[635..639] with) (NP (NP (JJ:[640..648] retinoid) (NN:[649..650] X) (NN:[651..659] receptor)) (NP (-LRB-:[660..661] -LRB-) (NN:[661..664] RXR) (-RRB-:[664..665] -RRB-))))) (VP (VBD:[667..677] stimulated) (NP (DT:[678..681] the) (NN:[682..690] promoter) (NN:[691..699] activity)) (PP (IN:[700..702] in) (NP (NP (DT:[703..706] the) (NN:[707..714] absence)) (PP (IN:[715..717] of) (NP (NN:[718..724] ligand))))) (,:[724..725] ,) (S-ADV (ADVP (RB:[726..733] however)) (,:[733..734] ,) (NP-SBJ (NP (NN:[735..743] addition)) (PP (IN:[744..746] of) (NP (NN:[748..752] atRA)))) (VP (VBD:[753..762] inhibited) (NP (DT:[763..766] the) (JJ:[767..782] transcriptional) (NN:[783..791] activity))))) (.:[791..792] .))) ;sentence 6 Span:793..895 ;Cotransfection with retinoic acid receptor (RAR) did not have much effect on ;CYP7A promoter activity. ;[813..836]:substance:"retinoic acid receptor" ;[838..841]:substance:"RAR" ;[871..876]:cyp450:"CYP7A" ;[877..885]:substance:"promoter" (SENT (S (NP-SBJ (NP (NN:[793..807] Cotransfection)) (PP (IN:[808..812] with) (NP (NP (JJ:[813..821] retinoic) (NN:[822..826] acid) (NN:[828..836] receptor)) (NP (-LRB-:[837..838] -LRB-) (NN:[838..841] RAR) (-RRB-:[841..842] -RRB-))))) (VP (VBD:[843..846] did) (RB:[847..850] not) (VP (VB:[851..855] have) (NP (NP (JJ:[856..860] much) (NN:[861..867] effect)) (PP (IN:[868..870] on) (NP (NN:[871..876] CYP7A) (NN:[877..885] promoter) (NN:[886..894] activity)))))) (.:[894..895] .))) ;sentence 7 Span:896..1091 ;The CYP7A promoter, when linked upstream to the SV40/ luciferase reporter ;gene, strongly repressed the phorbol 12-myristate 13-acetate ;(PMA)-stimulated SV40/ luciferase reporter gene activity. ;[900..905]:cyp450:"CYP7A" ;[907..915]:substance:"promoter" ;[1001..1032]:substance:"phorbol 12-myristate 13-acetate" ;[1034..1037]:substance:"PMA" (SENT (S (NP-SBJ (NP (DT:[896..899] The) (NN:[900..905] CYP7A) (NN:[907..915] promoter)) (,:[915..916] ,) (SBAR (WHADVP-2 (WRB:[917..921] when)) (S (NP-SBJ-1 (-NONE-:[921..921] *)) (VP (VBN:[922..928] linked) (NP-1 (-NONE-:[928..928] *)) (ADVP (RB:[929..937] upstream)) (PP-CLR (TO:[938..940] to) (NP (DT:[941..944] the) (NML (NN:[945..949] SV40) (SYM:[949..950] /) (NN:[951..961] luciferase)) (NN:[962..970] reporter) (NN:[971..975] gene))) (ADVP-TMP-2 (-NONE-:[975..975] *T*)))))) (,:[975..976] ,) (ADVP (RB:[977..985] strongly)) (VP (VBD:[987..996] repressed) (NP (DT:[997..1000] the) (NML (NML (NML (NML (NN:[1001..1008] phorbol) (NN:[1009..1021] 12-myristate) (NN:[1022..1032] 13-acetate)) (NML (-LRB-:[1033..1034] -LRB-) (NN:[1034..1037] PMA) (-RRB-:[1037..1038] -RRB-))) (HYPH:[1038..1039] -) (VBN:[1039..1049] stimulated)) (NML (NN:[1050..1054] SV40) (SYM:[1054..1055] /) (NN:[1056..1066] luciferase)) (NN:[1068..1076] reporter) (NN:[1077..1081] gene)) (NN:[1082..1090] activity))) (.:[1090..1091] .))) ;sentence 8 Span:1092..1200 ;The regions conferring the effects of RA and PMA were mapped to nt-176/ -117 ;and nt-148/-129, respectively. ;[1130..1132]:substance:"RA" ;[1137..1140]:substance:"PMA" (SENT (S (NP-SBJ-1 (NP (DT:[1092..1095] The) (NNS:[1096..1103] regions)) (VP (VBG:[1104..1114] conferring) (NP (NP (DT:[1115..1118] the) (NNS:[1119..1126] effects)) (PP (IN:[1127..1129] of) (NP (NN:[1130..1132] RA) (CC:[1133..1136] and) (NN:[1137..1140] PMA)))))) (VP (VBD:[1141..1145] were) (VP (VBN:[1147..1153] mapped) (NP-1 (-NONE-:[1153..1153] *)) (PP-LOC (TO:[1154..1156] to) (NP (NP (NN:[1157..1159] nt) (SYM:[1159..1160] -) (CD:[1160..1163] 176) (SYM:[1163..1164] /) (SYM:[1165..1166] -) (CD:[1166..1169] 117)) (CC:[1170..1173] and) (NP (NN:[1174..1176] nt) (SYM:[1176..1177] -) (CD:[1177..1180] 148) (SYM:[1180..1181] /) (SYM:[1181..1182] -) (CD:[1182..1185] 129)))) (,:[1185..1186] ,) (ADVP (RB:[1187..1199] respectively)))) (.:[1199..1200] .))) ;sentence 9 Span:1201..1306 ;Several direct repeats of hormone response element (AGTTCA) in this region ;are required for RA response. ;[1228..1235]:substance:"hormone" ;[1294..1296]:substance:"RA" (SENT (S (NP-SBJ-1 (NP (JJ:[1201..1208] Several) (JJ:[1209..1215] direct) (NNS:[1216..1223] repeats)) (PP (IN:[1224..1226] of) (NP (NN:[1228..1235] hormone) (NN:[1236..1244] response) (NN:[1245..1252] element) (PRN (-LRB-:[1253..1254] -LRB-) (NP (NN:[1254..1260] AGTTCA)) (-RRB-:[1260..1261] -RRB-)))) (PP-LOC (IN:[1262..1264] in) (NP (DT:[1265..1269] this) (NN:[1270..1276] region)))) (VP (VBP:[1277..1280] are) (VP (VBN:[1281..1289] required) (NP-1 (-NONE-:[1289..1289] *)) (PP (IN:[1290..1293] for) (NP (NN:[1294..1296] RA) (NN:[1297..1305] response))))) (.:[1305..1306] .))) ;sentence 10 Span:1308..1388 ;AP-1 like sequences are located within the region responding to both RA and ;PMA. ;[1308..1312]:substance:"AP-1" ;[1377..1379]:substance:"RA" ;[1384..1387]:substance:"PMA" (SENT (S (NP-SBJ-1 (NN:[1308..1312] AP-1) (NNS:[1318..1327] sequences)) (VP (VBP:[1328..1331] are) (VP (VBN:[1332..1339] located) (NP-1 (-NONE-:[1339..1339] *)) (PP-LOC (IN:[1340..1346] within) (NP (NP (DT:[1347..1350] the) (NN:[1351..1357] region)) (VP (VBG:[1358..1368] responding) (PP-CLR (TO:[1369..1371] to) (NP (DT:[1372..1376] both) (NN:[1377..1379] RA) (CC:[1380..1383] and) (NN:[1384..1387] PMA)))))))) (.:[1387..1388] .))) ;sentence 11 Span:1390..1486 ;Site-directed mutagenesis of the AP-1 site abolished the effects of both RA ;and phorbol esters. ;[1423..1427]:substance:"AP-1" ;[1463..1465]:substance:"RA" ;[1471..1485]:substance:"phorbol esters" (SENT (S (NP-SBJ (NP (ADJP (NN:[1390..1394] Site) (HYPH:[1394..1395] -) (VBN:[1395..1403] directed)) (NN:[1404..1415] mutagenesis)) (PP (IN:[1416..1418] of) (NP (DT:[1419..1422] the) (NN:[1423..1427] AP-1) (NN:[1428..1432] site)))) (VP (VBD:[1433..1442] abolished) (NP (NP (DT:[1443..1446] the) (NNS:[1447..1454] effects)) (PP (IN:[1455..1457] of) (NP (DT:[1458..1462] both) (NP (NN:[1463..1465] RA)) (CC:[1466..1469] and) (NP (NN:[1471..1478] phorbol) (NNS:[1479..1485] esters)))))) (.:[1485..1486] .))) ;sentence 12 Span:1487..1531 ;Retinoic acid effect was antagonized by PMA. ;[1487..1500]:substance:"Retinoic acid" ;[1527..1530]:substance:"PMA" (SENT (S (NP-SBJ-1 (JJ:[1487..1495] Retinoic) (NN:[1496..1500] acid) (NN:[1501..1507] effect)) (VP (VBD:[1508..1511] was) (VP (VBN:[1512..1523] antagonized) (NP-1 (-NONE-:[1523..1523] *)) (PP (IN:[1524..1526] by) (NP-LGS (NN:[1527..1530] PMA))))) (.:[1530..1531] .))) ;sentence 13 Span:1532..1679 ;Moreover, cotransfection of Fos and Jun expression vectors blunted the ;stimulatory effect of retinoic acid on the CYP7A/luciferase gene activity. ;[1627..1640]:substance:"retinoic acid" (SENT (S (ADVP (RB:[1532..1540] Moreover)) (,:[1540..1541] ,) (NP-SBJ (NP (NN:[1543..1557] cotransfection)) (PP (IN:[1558..1560] of) (NP (NP (NN:[1561..1564] Fos) (NML-1 (-NONE-:[1564..1564] *P*))) (CC:[1565..1568] and) (NP (NN:[1569..1572] Jun) (NML-1 (NN:[1573..1583] expression) (NNS:[1584..1591] vectors)))))) (VP (VBD:[1592..1599] blunted) (NP (NP (DT:[1600..1603] the) (JJ:[1604..1615] stimulatory) (NN:[1616..1622] effect)) (PP (IN:[1624..1626] of) (NP (JJ:[1627..1635] retinoic) (NN:[1636..1640] acid))) (PP (IN:[1641..1643] on) (NP (DT:[1644..1647] the) (NML (NML (NN:[1648..1653] CYP7A) (SYM:[1653..1654] /) (NN:[1654..1664] luciferase)) (NN:[1665..1669] gene)) (NN:[1670..1678] activity))))) (.:[1678..1679] .))) ;sentence 14 Span:1680..1785 ;Therefore, effects of two different signal transduction pathways converge to ;a common response element. (SENT (S (ADVP (RB:[1680..1689] Therefore)) (,:[1689..1690] ,) (NP-SBJ (NP (NNS:[1691..1698] effects)) (PP (IN:[1699..1701] of) (NP (CD:[1703..1706] two) (JJ:[1707..1716] different) (NML (NN:[1717..1723] signal) (NN:[1724..1736] transduction)) (NNS:[1737..1745] pathways)))) (VP (VBP:[1746..1754] converge) (PP (TO:[1755..1757] to) (NP (DT:[1758..1759] a) (JJ:[1760..1766] common) (NN:[1767..1775] response) (NN:[1777..1784] element)))) (.:[1784..1785] .))) ;sentence 15 Span:1786..1905 ;This regulatory cross-talk may be involved in bile acid repression and ;regulates CYP7 gene transcription in the liver. ;[1832..1841]:substance:"bile acid" (SENT (S (NP-SBJ-1 (DT:[1786..1790] This) (JJ:[1791..1801] regulatory) (NN:[1802..1807] cross) (HYPH:[1807..1808] -) (NN:[1808..1812] talk)) (VP (VP (MD:[1813..1816] may) (VP (VB:[1817..1819] be) (VP (VBN:[1820..1828] involved) (NP-1 (-NONE-:[1828..1828] *)) (PP-CLR (IN:[1829..1831] in) (NP (NN:[1832..1836] bile) (NN:[1837..1841] acid) (NN:[1842..1852] repression)))))) (CC:[1853..1856] and) (VP (VBZ:[1858..1867] regulates) (NP (NN:[1868..1872] CYP7) (NN:[1873..1877] gene) (NN:[1878..1891] transcription)) (PP-LOC (IN:[1892..1894] in) (NP (DT:[1895..1898] the) (NN:[1899..1904] liver))))) (.:[1904..1905] .))) ;section 16 Span:1909..1953 ;PMID: 8753804 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1909..1913] PMID) (::[1913..1914] :) (CD:[1915..1922] 8753804) (NN:[1923..1924] -LSB-) (NNP:[1924..1930] PubMed) (::[1931..1932] -) (NN:[1933..1940] indexed) (IN:[1941..1944] for) (NNP:[1945..1953] MEDLINE-RSB-)))